ArticleCancer medicine2025
Trends of Female Breast Cancer Incidence, Mortality, and Survival in Fujian Province of China: 2011-2020 and Projection to 2025.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The potential value of curcumin in breast cancer: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2026Pooled it
- Preparedness for generative AI adoption among Chinese cancer survivors: a multi-center cross-sectional survey study.Frontiers in public health · 2026Article
- Trends in breast cancer mortality and analysis of years of life lost among Chinese residents, 2013-2021.Frontiers in oncology · 2026Article
- Epidemiology, early detection, and management of breast cancer in China: A comprehensive review.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Trends of Female Breast Cancer Incidence, Mortality, and Survival in Fujian Province of China: 2011-2020 and Projection to 2025.Cancer medicine · 2025Article
- The role of circRNAs in NScience progressReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer was the second most common cancer and the fifth leading cause of cancer deaths among women in China, with increasing trends. Evaluating breast cancer trends and predicting future burdens can inform prevention strategies. This study aimed to analyze the trends in female breast cancer incidence, mortality, and survival in Fujian Province, southeastern China, between 2011 and 2020, and to project the future burden through 2025.
methodsPopulation-based cancer registry data from Fujian Province were collected during 2011-2020, with survival follow-up extending through March 2022, covering approximately 2.59 million women. Age-standardized incidence rates (ASIR) and mortality rates (ASMR) were calculated using Segi's world standard population. Temporal trends were assessed using Joinpoint regression analysis to determine average annual percentage change (AAPC). Relative survival were computed as the ratio of observed survival to expected survival. Autoregressive Integrated Moving Average (ARIMA) model was employed to predict incidence and mortality for 2021-2025.
resultsDuring 2011-2020, 8047 female breast cancer cases and 1754 deaths were recorded. The ASIR increased from 19.34/100,000 to 38.73/100,000, with an AAPC of 7.4% (95% CI: 3.6%-11.4%). The ASMR increased from 3.37/100,000 to 6.19/100,000, with an AAPC of 8.3% (95% CI: 4.3%-12.4%). Rural areas showed more rapid increases in both incidence and mortality than in urban areas. In 2011-2014, 2015-2017, and 2018-2020, the age-standardized 5-year relative survival rates were 64.10% (95% CI: 59.85-68.02), 69.35% (95% CI: 64.62-73.57), and 72.94% (95% CI: 68.5-76.86), with higher survival in urban areas and younger age groups. The ARIMA models projected continued increases in both ASIR and ASMR through 2025, reaching 46.41/100,000 and 8.46/100,000, respectively.
conclusionBreast cancer constitutes an escalating public health challenge in Fujian Province with disparities across age groups and urban and rural areas. Future strategies should prioritize healthcare equity and regional resource allocation to reduce mortality and enhance survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.